Money · Lobbying reports · 119th Congress
H.R. 4299
51 saved lobbying reports name H.R. 4299.
51 reports
Confirmed from the official recordSenate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Lobbying Disclosure Act reports, LDA.gov. This copy was read November 22, 2026 at 1:29 PM Eastern.
Reports that name this bill
The amount is what the report gives for the whole quarter: everything the registrant did for that client, all issues together. A linked name opens that organization’s page on this site.
| Registrant, sort A to Z | Client, sort A to Z | Amount for the whole quarter, sort largest first | Quarter, sort A to Z | Filed | Report |
|---|---|---|---|---|---|
| MAXWELL CREEK STRATEGIC CONSULTING LLC | PACT COALITION | $50,000.00reported as income | July to September 2026 | Open the report | |
| COMMUNITY ONCOLOGY ALLIANCE | COMMUNITY ONCOLOGY ALLIANCE | $265,800.00reported as expenses | July to September 2026 | Open the report | |
| MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY | MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY | $610,000.00reported as expenses | July to September 2026 | Open the report | |
| CENCORA, INC. | CENCORA, INC. | $405,804.00reported as expenses | July to September 2026 | Open the report | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $7,040,000.00reported as expenses | July to September 2026 | Open the report | |
| BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $3,050,000.00reported as expenses | July to September 2026 | Open the report | |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1,530,000.00reported as expenses | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | BRISTOL-MYERS SQUIBB | $80,000.00reported as income | July to September 2026 | Open the report | |
| WILLIAMS AND JENSEN, PLLC | ABBVIE, INC. | $90,000.00reported as income | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | TAKEDA PHARMACEUTICALS AMERICA, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| AMGEN, INC. | AMGEN INC | $3,150,000.00reported as expenses | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | MERCK & CO. INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) | $60,000.00reported as income | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | GENENTECH USA, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | BRISTOL-MYERS SQUIBB COMPANY | $60,000.00reported as income | July to September 2026 | Open the report | |
| AVENUE SOLUTIONS | AMGEN, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| ABBVIE, INC. | ABBVIE INC. | $1,050,000.00reported as expenses | July to September 2026 | Open the report | |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $2,220,000.00reported as expenses | July to September 2026 | Open the report | |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $50,000.00reported as expenses | July to September 2026 | Open the report | |
| CARDINAL HEALTH, INC. | CARDINAL HEALTH INC | $400,000.00reported as expenses | July to September 2026 | Open the report | |
| FARRAGUT PARTNERS LLP | TAKEDA PHARMACEUTICALS AMERICA INC | $50,000.00reported as income | July to September 2026 | Open the report | |
| FARRAGUT PARTNERS LLP | PACT COALITION | $130,000.00reported as income | July to September 2026 | Open the report | |
| STANTON PARK GROUP | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | $60,000.00reported as income | July to September 2026 | Open the report | |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $1,450,000.00reported as expenses | July to September 2026 | Open the report | |
| ARTHRITIS FOUNDATION | ARTHRITIS FOUNDATION | $75,000.00reported as expenses | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60,000.00reported as income | July to September 2026 | Open the report | |
| FARRAGUT PARTNERS LLP | GENENTECH | $50,000.00reported as income | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | LARGE UROLOGY GROUP PRACTICE ASSOCIATION | $90,000.00reported as income | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | INFUSION PROVIDERS ALLIANCE | $90,000.00reported as income | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | GILEAD SCIENCES, INC. | $60,000.00reported as income | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | GENENTECH | $50,000.00reported as income | July to September 2026 | Open the report | |
| THE MCMANUS GROUP | AMGEN | $60,000.00reported as income | July to September 2026 | Open the report | |
| B HALL STRATEGIES, LLC | TIBER CREEK GROUP OBO ABBVIE INC. | $20,000.00reported as income | July to September 2026 | Open the report | |
| B HALL STRATEGIES, LLC | TIBER CREEK GROUP ON BEHALF OF DAIICHI SANKYO, INC. | $30,000.00reported as income | July to September 2026 | Open the report | |
| B HALL STRATEGIES, LLC | TIBER CREEK GROUP ON BEHALF OF TAKEDA PHARMACEUTICALS AMERICA, INC. | $30,000.00reported as income | July to September 2026 | Open the report | |
| B HALL STRATEGIES, LLC | TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF GENENTECH, INC. | $30,000.00reported as income | July to September 2026 | Open the report | |
| B HALL STRATEGIES, LLC | TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF PHRMA | $50,000.00reported as income | July to September 2026 | Open the report | |
| TIBER CREEK GROUP | ABBVIE INC. | $30,000.00reported as income | July to September 2026 | Open the report | |
| DAIICHI SANKYO, INC. | DAIICHI SANKYO INC | $370,000.00reported as expenses | July to September 2026 | Open the report | |
| TIBER CREEK GROUP | DAIICHI SANKYO, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| TIBER CREEK GROUP | TAKEDA PHARMACEUTICALS AMERICA, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| TIBER CREEK GROUP | MERCK & CO., INC | $50,000.00reported as income | July to September 2026 | Open the report | |
| NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | $30,000.00reported as income | July to September 2026 | Open the report | |
| FERRING PHARMACEUTICALS, INC. | FERRING PHARMACEUTICALS, INC. | $260,000.00reported as expenses | July to September 2026 | Open the report | |
| ALLIANCE FOR AGING RESEARCH | ALLIANCE FOR AGING RESEARCH | $65,000.00reported as expenses | July to September 2026 | Open the report | |
| INFUSION PROVIDERS ALLIANCE | INFUSION PROVIDERS ALLIANCE | $110,000.00reported as expenses | July to September 2026 | Open the report | |
| TODD STRATEGY GROUP | BRISTOL-MYERS SQUIBB COMPANY | $80,000.00reported as income | July to September 2026 | Open the report | |
| TODD STRATEGY GROUP | TAKEDA PHARMACEUTICALS AMERICA, INC. | $50,000.00reported as income | July to September 2026 | Open the report | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | $80,000.00reported as expenses | July to September 2026 | Open the report | |
| LUPUS FOUNDATION OF AMERICA | LUPUS FOUNDATION OF AMERICA | $6,700.00reported as expenses | July to September 2026 | Open the report |
Reports 1 to 50 of 51Later in the list